Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00193583 · ClinicalTrials.gov registry record · Phase 1
Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Refractory and/or Advanced Solid Tumors
A Phase 1 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00193583 is a Phase 1 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 18 participants.
The verdict
NCT00193583, a Phase 1 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
In this phase I study we will characterize the safety, tolerability, maximum tolerated dose and dose-limiting toxicity of weekly bolus topotecan when administered in combination with two different dosing schedules of carboplatin. We will also evaluate any antitumor activity of these combination regimens.
Interventions
- DRUG Carboplatin
- DRUG Topotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2003-05 |
| Est. Completion | 2005-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00193583
The ClinicalTrials.gov registry entry for NCT00193583 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carboplatin is the first listed.
NCT00193583 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00193583 about?
NCT00193583 is a clinical study titled "Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Refractory and/or Advanced Solid Tumors". In this phase I study we will characterize the safety, tolerability, maximum tolerated dose and dose-limiting toxicity of weekly bolus topotecan when administered in combination with two different dosing schedules of carboplatin. We will also evaluate any antitumor activity of these combination regi...
What is the current status of trial NCT00193583?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2003-05. Estimated completion is 2005-05.
What interventions are being tested in trial NCT00193583?
The interventions under investigation include: Carboplatin (DRUG), Topotecan (DRUG).
Who is sponsoring clinical trial NCT00193583?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.